371 related articles for article (PubMed ID: 12730635)
1. Platelets and antiplatelet therapy in patients with diabetes mellitus.
Arjomand H; Roukoz B; Surabhi SK; Cohen M
J Invasive Cardiol; 2003 May; 15(5):264-9. PubMed ID: 12730635
[TBL] [Abstract][Full Text] [Related]
2. [Platelet aggregation inhibitors in diabetes mellitus].
Abrahamian H
Acta Med Austriaca; 1999; 26(5):137-41. PubMed ID: 11512189
[TBL] [Abstract][Full Text] [Related]
3. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
[TBL] [Abstract][Full Text] [Related]
4. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
Serebruany V; Pokov I; Kuliczkowski W; Chesebro J; Badimon J
Thromb Haemost; 2008 Jul; 100(1):76-82. PubMed ID: 18612541
[TBL] [Abstract][Full Text] [Related]
5. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
6. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M
Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294
[TBL] [Abstract][Full Text] [Related]
7. Targeting the use of glycoprotein IIb/IIIa antagonists--the diabetic patient.
Meier-Ewert HK; Nesto RW
Rev Cardiovasc Med; 2002; 3 Suppl 1():S20-7. PubMed ID: 12439433
[TBL] [Abstract][Full Text] [Related]
8. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Angiolillo DJ; Bernardo E; Sabaté M; Jimenez-Quevedo P; Costa MA; Palazuelos J; Hernández-Antolin R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Guzman LA; Bass TA; Macaya C; Fernandez-Ortiz A
J Am Coll Cardiol; 2007 Oct; 50(16):1541-7. PubMed ID: 17936152
[TBL] [Abstract][Full Text] [Related]
9. Diabetic specific aspects in antithrombotic therapy in patients with coronary artery disease.
Farhan S; Höchtl T; Wojta J; Huber K
Minerva Med; 2010 Aug; 101(4):239-53. PubMed ID: 21030936
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Konstantopoulos K; Mousa SA
Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
[TBL] [Abstract][Full Text] [Related]
11. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of patients with diabetes mellitus type 2 and coronary artery disease].
Wiersma JJ; Trip MD; Piek JJ
Ned Tijdschr Geneeskd; 2006 Feb; 150(7):361-6. PubMed ID: 16523798
[TBL] [Abstract][Full Text] [Related]
13. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.
Cooke GE; Liu-Stratton Y; Ferketich AK; Moeschberger ML; Frid DJ; Magorien RD; Bray PF; Binkley PF; Goldschmidt-Clermont PJ
J Am Coll Cardiol; 2006 Feb; 47(3):541-6. PubMed ID: 16458133
[TBL] [Abstract][Full Text] [Related]
14. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
Harrington RA
Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
[TBL] [Abstract][Full Text] [Related]
15. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
17. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
[No Abstract] [Full Text] [Related]
18. The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines.
Hostetter JC; Bhatt DL
Minerva Cardioangiol; 2003 Oct; 51(5):531-46. PubMed ID: 14551522
[TBL] [Abstract][Full Text] [Related]
19. Platelet hyperprocoagulant activity in Type 2 diabetes mellitus: attenuation by glycoprotein IIb/IIIa inhibition.
Razmara M; Hjemdahl P; Ostenson CG; Li N
J Thromb Haemost; 2008 Dec; 6(12):2186-92. PubMed ID: 18983513
[TBL] [Abstract][Full Text] [Related]
20. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
